Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker’s results higher.
What Wall Street Analysts Think of Novo Nordisk’s Stock Ahead of Earnings
view original post